News for Botanix Pharmaceuticals Limited (BOT.AX)

The ASX200 closed down 0.9% at 7,890 points. It was a bloodbath…

Bitcoin jumped to an all-time record high above $US107,000 after Donald Trump confirmed plans for a U.S. strategic reserve for the cryptocurrency.

The ASX200 reversed its trend to end the week in the green, up 0.35%. Nearly all sectors made gains, with Utilities up the most, by 1.9%. Discretionary dipped the most, down 0.4%, Materials and Industrials followed, both falling short, but only just.

It's looking like another red day with the ASX flattish around intraday trades. Healthcare leads the decline at 0.7%, followed by IT - down half a percent.

Botanix on Thursday described itself as having transitioned from a development stage to being revenue-generating dermatology company.

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription treatment for underarm sweating.

Botanix Pharmaceuticals (ASX:BOT) has completed the planned human factors (HF) validation study for Sofdra, evaluating revised instructions for use (IFU).

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional and sophisticated investors to accelerate commercial activities in the US to increase revenue turnaround.

Botanix Pharmaceuticals (ASX:BOT) has had its application to use the novel sofpironium bromide gel to treat primary axillary hyperhidrosis rejected by the US FDA.

Botanix Pharmaceuticals (ASX:BOT) has appointed Dr Howie McKibbon as its newest Chief Executive Officer, effective from August 24.

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower.

Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and...

Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value...

In early trade, the consumer staples sector gained more than a per cent, and energy, 0.8 per cent.

On Stockhead today, We unpack what just happened on local (and global) markets in Q1 and March. It's RBA Tuesday. Come get your forecasts.

The ASX closes 0.5% higher, led into gains in Energy and Tech as Olympia stacks on some serious weight on news of a Liontown farm-in.

RNA therapies specialist PYC Therapeutic (ASX:PYC) says it will now progress a second drug development program to human trial.

Botanix Pharmaceuticals (ASX:BOT) Dr Howie McKibbon believes Aussie Investors are comfortable backing early-stage, high-risk companies.

Will 2023 be the Year of the, uh... sand, are we mad for going cold on gold, and a shiny s..tcoin for you if you know what an Ordinal is.